Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel

Drug manufacturers need more clarity from FDA regarding post-marketing studies, industry representatives told the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System